Compare Hut 8 Corp (HUT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hut 8 Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Hut 8 Corp trades at $95.49 (market cap $10.94B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12.3× Hut 8 Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.
| HUT | VRTX | |
|---|---|---|
Market Cap | $10.94B | $134.25B |
Sector | Technology | Health |
52-Week High | $133.02 | $529.65 |
52-Week Low | $21.37 | $376.62 |
Enterprise Value | $18.38B | $128.37B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
